Drugs / 90Y Zevalin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00477815 | May 2005 → Jul 2011 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01207765 | Apr 2008 → Jan 2013 | plasma cell myeloma | Tufts Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT00193505 | Oct 2003 → Aug 2005 | non-Hodgkin lymphoma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-Zevalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00477815 ↗ |
| Modality | Monoclonal antibody | “Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells.” NCT00477815 ↗ |
| Route | Intravenous | “Patients with acceptable biodistribution receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14” NCT00477815 ↗ |